reports
- Blair Levin
NSR Policy: The Interconnections of ACP, Spectrum, Title II, and the S...
In this weekend update, we reconsider our initial takes on several events last week and how they could be affected by events this week. Specifically, we look at the interplay of the FCC’s Title II Order, the Second Circuit opinion upholding New York State’s mandate for ISPs to offer low-income households a low-cost broadband offering, Senator Cantwell’s draft spectrum bill, and how all are affected by the end of ACP funding in the next few weeks.
- Blair Levin
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
LL LUMBER LIQUIDATORS HOLDINGS INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
TSC TRISTATE CAPITAL HOLDINGS INC
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
ACET ADICET BIO INC
ASO ACADEMY SPORTS AND OUTDOORS
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
SBTX SILVERBACK THERAPEUTICS
TNGX TANGO THERAPEUTICS
LBPH INC
IKNA LONGBOARD PHARMACEUTICALS
TCRX IKENA ONCOLOGY INC
VERA TSCAN THERAPEUTICS INC
HOWL VERA THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
AVTE MONTE ROSA THERAPEUTICS INC
CMPX AEROVATE THERAPEUTICS INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
VIGL JANUX THERAPEUTICS INC
MLTX VIGIL NEUROSCIENCE INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
PEPG TYRA BIOSCIENCES INC
HR PEPGEN INC
EWTX HEALTHCARE TRUST OF AMERICA INC.
PRME EDGEWISE THERAPEUTICS INC
OCS PRIME MEDICINE INC
APGE OCULIS HOLDING AG
DNTH APOGEE THERAPEUTICS INC
DIANTHUS THERAPEUTICS INC
- Blair Levin
NSR Policy Update: Will ACP be Saved by Discharge Petition?
Tuesday, Rep. Yvette Clarke (D–New York) filed a discharge petition calling for a floor vote on the ACP Extension Act. The petition requires 218 signatures to be successful. In this note we analyze whether this effort is likely to be successful.
- Blair Levin
NSR Policy: The DoD’s Spectrum Game
This week we cover spectrum issues, with a particular focus on the implications of last week’s Department of Defense (DoD) report on the feasibility of sharing the 3.1 – 3.45GHz band with wireless carriers. Our New Street colleagues published a note describing the report and its implications for DISH/SATS, T, VZ, and TMUS.
- Jonathan Chaplin
SATS: Shuffling Assets and Cash
Last week, EchoStar released its 10-K’s for DBS, Dish Networks, and Hughes. With these filings, we can see all the movements of cash between entities in the fourth quarter, and most of the shuffling in the first quarter. In this note, we review these cash transfers as well as the internal spectrum sale that helped fund Networks through the first quarter.
- Jonathan Chaplin
DoD spectrum report released – implications for Dish, Verizon, AT&T, a...
The DoD released its report on the feasibility of sharing the 3.1 – 3.45GHz band with Wireless Carriers. The report concludes that sharing is feasible if certain conditions are met. It also makes clear that meeting the conditions will be challenging. The ability of carriers to share the band, and the timing of its availability have important implications for the value of Dish’s spectrum and for the businesses of the national carriers generally. We cover both in this brief report.
RPM Reports Record Fiscal 2024 Third-Quarter Results
MEDINA, Ohio--(BUSINESS WIRE)-- RPM International Inc. (NYSE: RPM), a world leader in specialty coatings, sealants and building materials, today reported record financial results for its fiscal 2024 third quarter ended February 29, 2024. “Thanks to the hard work of RPM associates, our third-quarter results demonstrated our continued ability to grow sales, expand margins and improve cash flow in a mixed economic environment. This is due to our strategic balance, our focus on repair and maintenance and our MAP 2025 operating improvement initiatives, which are driving structural financial impro...
- Blair Levin
NSR Policy: Net Neutrality: It’s Back!
This week, we focus on the FCC’s upcoming Net Neutrality order, which is likely to be made public on Thursday and voted on April 25. The big picture is that the item will be approved on a 3-2 vote and largely resemble the 2015 order. As we have been in the past, we are skeptical that the rules will be material to the financial performance of the ISPs but there are a few interesting nuances to this iteration.
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spannin...
RPM Declares Quarterly Dividend
MEDINA, Ohio--(BUSINESS WIRE)-- (NYSE: RPM) today announced that its board of directors declared a regular quarterly cash dividend of $0.46 per share, payable on April 30, 2024, to stockholders of record as of April 19, 2024. RPM’s last cash dividend increase of 10% in October 2023 marked RPM’s 50th consecutive year of increased cash dividends paid to its stockholders, which places RPM in an elite category of less than half of 1 percent of all publicly traded U.S. companies. Only 41 other U.S. companies, besides RPM, have consecutively paid an increasing annual dividend for a longer period ...
- Wedbush Research
KMX CARMAX INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NCMI NATIONAL CINEMEDIA INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IMAX IMAX CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
DHI D.R. HORTON INC.
FRX_CN FENNEC PHARMACEUTICALS
PVH PVH CORP.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
CURA CURALEAF HOLDINGS
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
Avalo Reports 2023 Financial Results and Provides Business Updates
Avalo Reports 2023 Financial Results and Provides Business Updates Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 millionTopline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023....
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results a...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharma...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financin...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq...
- Blair Levin
NSR Policy: FCC Dings Nexstar for Exceeding Ownership Limits but Real ...
Last week, the FCC ruled that Nexstar’s relationship with Mission Broadcasting’s WPIX in New York City violated its rules and the national broadcast ownership cap. In this note, we discuss how this decision reflects the priorities of the current FCC, but also broader themes related to the decline of linear television and upcoming changes to both the market and the video regulatory environment.
TMUS T-MOBILE US INC.
VZ VERIZON COMMUNICATIONS INC.
T AT&T INC.
SBGI SINCLAIR BROADCAST GROUP INC. CLASS A
NXST NEXSTAR MEDIA GROUP INC. CLASS A
GOOGL ALPHABET INC. CLASS A
DISH DISH NETWORK CORPORATION CLASS A
DIS WALT DISNEY COMPANY
CHTR CHARTER COMMUNICATIONS INC. CLASS A
AMZN AMAZON.COM INC.
FOX FOX CORPORATION CLASS B
WBD WARNER BROS. DISCOVERY INC.
- Blair Levin
NSR Policy: State of Play of BEAD
In 2024-25, one of the biggest events in the telecom sector will be how the federal government and states spend the $42.5 billion Congress appropriated for deployment to unserved and underserved locations as part of the BEAD program. In this Weekend Update, we provide a state of play on the program, including outlining the process going forward, the timing, the Fiber v. FWA debate, what has worked, what challenges lie ahead, the election impact (or lack thereof) and the quick take from the compa...
Frequency Electronics Issues a Clarification to Yesterday’s Earnings C...
Frequency Electronics Issues a Clarification to Yesterday’s Earnings Call MITCHEL FIELD, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM). On yesterday’s earnings call, the Company discussed program charges that adversely affected its gross margins for the quarter ended January 31, 2024. As a result of percentage of completion accounting, these charges included a temporary reversal of revenue. The Company expects to recover approximately $1.2 million of this revenue during this calendar year. Because the costs have been conservati...
Frequency Electronics, Inc. Announces Third Quarter and Fiscal Year 20...
Frequency Electronics, Inc. Announces Third Quarter and Fiscal Year 2024 Financial Results MITCHEL FIELD, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is reporting revenues for the three-month and nine-month periods of fiscal 2024, ended January 31, 2024, of approximately $13.7 million and $39.7 million, respectively, compared to revenues of $10.6 million and $27.8 million, respectively, for the same periods of fiscal year 2023, ended January 31, 2023. Operating loss for the third quarter of fiscal year 2024 was $0.5 million c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.